{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A Survey-Based Comparative Analysis of Beta Blockers in Coronary Artery Disease (COMPCAD Survey)
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Survey Questionnaire Form

  1. Which of the following is a cardio selective beta blocker used in CAD? *

  2. Which beta blocker has additional α1-blocking properties, providing vasodilatory effects? *

  3. Can you explain the role of beta blockers in the management of coronary artery disease (CAD) and how they affect myocardial oxygen demand? *
  4. Based on your experience, could you compare the use of cardioselective versus non- selective beta blockers in the treatment of coronary artery disease (CAD)? *
  5. What is the primary mechanism by which beta blockers improve outcomes in CAD? *

  6. Which of the following beta blockers is NOT cardioselective? *

  7. Which beta blocker is primarily excreted renally and requires dose adjustment in renal impairment? *

  8. Which formulation of metoprolol is typically used for once-daily dosing? *

  9. Explain why carvedilol is preferred over atenolol in CAD with heart failure. *
  10. Based on your experience, could you explain why you prefer prescribing metoprolol for patients with coronary artery disease (CAD)? *
  11. Which beta blocker has the strongest evidence in reducing mortality post-MI? *

  12. Which beta blocker is preferred in CAD patients with concomitant heart failure? *

  13. Which beta blocker is preferred for patients with both CAD and diabetes? *

  14. Can you provide insights into why metoprolol succinate might be preferred over metoprolol tartrate for treating coronary artery disease (CAD) patients? *
  15. What are the primary adverse effects of beta blockers in patients with coronary artery disease (CAD), and what strategies can be used to manage these side effects effectively? *
  16. Which of the following beta blockers is least effective at reducing post-MI mortality? *

  17. Which beta blocker has been shown to reduce angina frequency significantly? *

  18. Which beta blocker is preferred for patients with both CAD and chronic obstructive pulmonary disease (COPD)? *

  19. What is the typical starting dose of metoprolol succinate for CAD patients? *

  20. Beta blockers can be used in combination with which of the following drug classes for better management of CAD? *

  21. Which of the following is a contraindication for beta blocker use in CAD? *

  22. Which beta blocker has the highest risk of causing central nervous system side effects? *

  23. How do you assess the importance of beta blocker discontinuation and the potential rebound effects in patients with coronary artery disease (CAD)? *
  24. With your experience in treating stable angina, how do beta blockers help, and what mechanisms are involved in symptom relief? *
  25. Which of the following beta blockers has the longest half-life? *

  26. How do you approach managing the side effects of beta blockers in your CAD patients, particularly those with comorbid conditions like diabetes or COPD? Can you provide an example of a challenging case and how you addressed it? *
  27. In the study by Emery et al., what was the correlation between early beta-blocker therapy and long-term outcomes in NSTEMI patients? *

  28. Which of the following is a common side effect of metoprolol? *

  29. Which landmark trials conclusively showed that selected beta blockers had mortality benefits of up to 30–35% in patients with heart failure with reduced ejection fraction (HFrEF)? *

  30. Based on your clinical experience, how have you observed the heart rate lowering effect of beta blockers impacting patients with heart failure with reduced ejection fraction (HFrEF)? Specifically, what range of heart rate reduction have you found to be most beneficial in improving patient outcomes? *
  31. What specific factors do you consider when choosing a beta blocker for a patient with coronary artery disease (CAD)? Could you share your personal experiences and insights on how these factors influence your decision-making process? *
  32. What was a significant finding of the EARLY-BAMI trial regarding IV metoprolol administration before primary PCI in STEMI patients? *

  33. Based on your clinical experience, what do you consider to be the most significant limitation in the current clinical studies analyzing the efficacy of beta-blocker therapy in CAD patients? How has this limitation impacted your clinical practice and decision- making? *
  34. What future development could potentially improve the efficacy of beta blockers in CAD treatment? *

  35. Can you describe a situation where you had to discontinue beta blocker therapy in a CAD patient? What were the reasons and how did you manage the transition? *
  36. What is a proposed but unproven mechanism by which beta blockers might reduce MI hospitalizations in geriatric patients with stable CAD? *

  37. In your experience, how do beta blockers impact the quality of life for CAD patients? Are there any particular patient feedback or observations you can share? *
  38. What do current Clinical Practice Guidelines state about initiating and continuing BB therapy following MI in patients without heart failure or LVSD? *

  39. Based on your clinical practice, what have been the most notable outcomes (both positive and negative) of using beta blockers in CAD patients? Can you share any success stories or challenges? *
  40. What strategies do you use to educate your CAD patients about the benefits and risks of beta blocker therapy? Can you describe a situation where patient education significantly improved adherence? *